Zetta Venture Partners is a San Francisco venture investor backing AI-native B2B applications, infrastructure and developer tools at inception, pre-seed and seed, with selective later follow-ons. Scientific investment examples include computational biology and EnsoData EEG diagnostic analysis. Historical USD1–3m initial commitments were stated in2020; current numeric check policy has not been independently verified. Official releases describe formation in2013, while first fund launch is described as2015.
Founded —
Type Venture capital 4 Zetta Venture Partners Fund IV 2025-05-30 2025-05-30 — FormD/AUSD150m offering, USD85395000 sold USD64605000 remaining; firstsale2024-05-31. No finalcloseverified; notAUM.
Zetta Venture Partners Fund III 2020-04-14 2020-04-14 $180M Announced thirdFundUSD180m, exact legal close unknown. 2020AUMUSD365m not current; historical initial commitmentsUSD1–3m not universalcurrent policy.
Zetta Venture Partners Fund II 2016-10-04 2016-10-04 $100M Closed secondFundUSD100m; 2016AUMUSD160m separate, founded2013 versus fundlaunch2015.
Zetta Venture Partners Fund I — — First intelligent-enterprise-software fund. Existence is established by the firm's second-fund announcement; this source does not directly disclose its size or close date.
SHOW MORE
$5M $1M – $10M San Francisco, California $5M $1M – $10M Alexandria, Virginia $5M $1M – $10M San Francisco Bay Area $2M $100K – $5M Brazil $2M $1M – $5M New York, New York $1M $500K – $5M San Francisco, California $1M $750K – $4M San Francisco, California $800K $100K – $1M San Francisco, California $500K $300K – $750K San Francisco Bay Area
SHOW MORE
$— 2026-07-15 Pulse Security Zetta Venture Partners $13M 2026-02-03 Phylo Zetta Venture Partners $— 2026 Pulse Security Zetta Venture Partners $28M 2026 Naive Y Combinator , Liquid 2 Ventures , Nexus Venture Partners , Zetta Venture Partners , Gokul Rajaram $30M 2025-10-22 Sumble Zetta Venture Partners , Anthony Goldbloom $— 2025-07-29 Nebulock Bain Capital , In-Q-Tel , Avid Ventures , Decibel , Zetta Venture Partners , Step Function $20M 2025-06-25 Ensodata Zetta Venture Partners $8M 2024-11-19 JIMINI HEALTH Zetta Venture Partners , BoxGroup , Dylan Reid $— 2024-04-03 Allure Security Zetta Venture Partners $— 2024-03-22 Cleric Zetta Venture Partners $7M 2024-03-11 Guardrails AI Zetta Venture Partners , Pear VC $9M 2023-12-07 DataCebo Zetta Venture Partners , Mark Gorenberg $7M 2023-09-12 Gable Crane Venture Partners , Zetta Venture Partners , Apoorva Pandhi , Scott Sage $5M 2023-06-15 Telmai Y Combinator , .406 Ventures , Zetta Venture Partners , Glasswing Ventures $50M 2023-04-21 Weaviate Cortical Ventures , Zetta Venture Partners $— 2023-03-30 Fixie Zetta Venture Partners $— 2023-01-25 Argilla Zetta Venture Partners $— 2023 Fixie.ai Zetta Venture Partners $— 2023 Tabular Andreessen Horowitz , Zetta Venture Partners $20M 2022-06-03 Ensodata Zetta Venture Partners $— 2022-05-20 Galley Zetta Venture Partners $— 2022-03-30 Skan AI Zetta Venture Partners $— 2022-03-23 Trustero Zetta Venture Partners $— 2022-02-10 Allure Security Zetta Venture Partners $— 2022 Promethium Zetta Venture Partners $— 2022 Verusen Zetta Venture Partners $11M 2021-12-07 Nabla Bio Khosla Ventures , Fifty Years , Zetta Venture Partners , Cantos $9M 2020-05-29 Ensodata Zetta Venture Partners , Mark Gorenberg $25M 2020-05-12 Lilt Sequoia , SEEDS Capital , Redpoint Ventures , Intel Capital , In-Q-Tel , Zetta Venture Partners $— 2019-09-25 VideaHealth Zetta Venture Partners $— 2019-03-19 Marketing Evolution Zetta Venture Partners $11M 2018-07-31 TEST.AI Gradient Ventures , Anna Patterson , Uncork Capital , Zetta Venture Partners , Andy McLoughlin $5M 2018-06-19 Falkonry Basis Set Ventures , Zetta Venture Partners , Mark Gorenberg , Lan Xuezhao $— 2017 Xant Zetta Venture Partners $— Unknown date Myia Zetta Venture Partners $— Unknown date Trustero Zetta Venture Partners $— Unknown date Guardrails Zetta Venture Partners $— Unknown date Golioth Zetta Venture Partners $— Unknown date Pimloc Zetta Venture Partners $— Unknown date Jimini Zetta Venture Partners $— Unknown date Jimini Zetta Venture Partners $37M Unknown date Faro AI General Catalyst , Northpond Ventures , S32 , Zetta Venture Partners , Merck Global Health Innovation Fund , Ankona Capital $25M Unknown date Nebulock Bain Capital , FirstMark Capital , Decibel , Zetta Venture Partners , Step Function $28M 2026-01-08 Boltz Zetta Venture Partners , Dylan Reid $— 2023-12-13 Featureform Zetta Venture Partners $15M 2021-06-08 Faro Health S32 , Section 32 , Northpond Ventures , Polaris Partners , Zetta Venture Partners $— Unknown date InsideSales Zetta Venture Partners $— Unknown date Aptology Zetta Venture Partners $— Unknown date Myia Health Zetta Venture Partners $— Unknown date Myia Health Zetta Venture Partners $— Unknown date Gable Ai Zetta Venture Partners $— Unknown date Gable Ai Zetta Venture Partners
SHOW MORE
team@apexlogos.ai · 5 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size and status
| Vehicle / metric | Amount (USD) | Date and status | Evidence and caveats |
| --- | --- | --- | --- |
| Fund I, historical | $60 million | Historical amount; close date not established here | Signal's first-fund claim is consistent with the 2016 release's $160 million total AUM less its $100 million Fund II. This arithmetic corroborates scale, not a precise Fund I closing date. |
| Fund II | $100 million | Closed, announced 2016-10-04 | [Firm-issued announcement](https://www.prnewswire.com/news-releases/zetta-closes-100m-expanding-the-first-fund-focused-on-intelligent-enterprise-software-300338889.html ) explicitly calls this its second fund and reports $160 million AUM at that time. |
| Fund III | $180 million | Fund announced 2020-04-14 | [Firm-issued announcement](https://www.prnewswire.com/news-releases/zetta-venture-partners-fuels-the-future-of-ai-with-180-million-fund-301040135.html ) identifies its third fund and $365 million total AUM. It describes an announced fund rather than an unraised target; the exact legal final-close date was not established. |
| Fund IV, L.P. | $150 million offering; $85.395 million sold; $64.605 million remaining | SEC Form D/A filed 2025-05-30; first sale 2024-05-31 | [SEC filing](https://www.sec.gov/Archives/edgar/data/2024392/000202439225000001/xslFormDX08/primary_doc.xml ), CIK 2024392. Formed in 2024; 34 investors reported. Amount sold is a fundraising snapshot, not proof of a $150 million final close. |
Fund IV is the latest-known vehicle located in these checks, not a claim that no later fund exists. No newer official close announcement was verified through searches for 2025–2026 fundraising. The $365 million AUM figure is dated 2020 and is not current AUM. The 2016 and 2020 AUM totals should not be mechanically reconciled by summing initial announced fund amounts: later upsizing or other capital may explain the difference, but was not established. Fund size, AUM, portfolio round totals and individual checks remain separate metrics.
Additional fund evidence checked in the final pass:
- Zetta Venture Partners Fund I: [source](https://www.prnewswire.com/news-releases/zetta-closes-100m-expanding-the-first-fund-focused-on-intelligent-enterprise-software-300338889.html ).
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Zetta Venture Partners Fund I | Undisclosed / unverified | Unknown |
| Zetta Venture Partners Fund II | USD 100000000 | 2016-10-04 |
| Zetta Venture Partners Fund III | USD 180000000 | 2020-04-14 |
| Zetta Venture Partners Fund IV | Undisclosed / unverified | 2025-05-30 | SHOW MORE
team@apexlogos.ai · 5 hours ago
Match research 2026-10-06 / GoldiZettaVenturePartners / sha256:e7b8393dfdffc62589289ef68ef84e89b9820f9d7ef916cb98cc9db18bfe95d4 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
Guardrails AI is independently confirmed as a $7.5 million seed led by Zetta by its [transaction counsel](https://www.lowenstein.com/news-insights/firm-news/lowenstein-represents-zetta-venture-partners-in-seed-funding-round-in-guardrails-ai ), March 2024. It develops AI assurance tools. This supports AI infrastructure exposure, but the label “AI” alone does not demonstrate scientific deep tech; it is not used here as the strongest deep-tech example. Ordinary enterprise SaaS records in the snapshot were not automatically classified as deep tech.
## Previous neurotech investments and adjacent companies
**EnsoData is verified exposure to EEG-based neurodiagnostic analysis.** The [FDA EnsoSleep record K162627](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K162627 ) classifies the device as automatic event detection for polysomnography with electroencephalograph, under neurology, with a 2017-03-31 substantial-equivalence decision. The [FDA K210034 summary](https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210034.pdf ), prepared 2021-06-08, describes software analyzing physiological signals for sleep staging and events with clinician review. Coupled with the dated company funding releases above, this is direct firm attribution and a concrete neural-signal technology rationale. It is analysis software; do not describe it as an implanted neural interface, BCI, stimulation system, or dedicated neurotech fund mandate. Some newer EnsoData offerings analyze peripheral PPG signals, which are not themselves neural recordings.
**Jimini Health is adjacent mental health, not verified direct neurotechnology.** Its [company-issued announcement](https://www.globenewswire.com/news-release/2024/11/19/2983540/0/en/Jimini-Health-Launches-with-8M-in-Funding-to-Transform-Mental-Health-with-Responsible-AI-Supported-Therapy.html ), 2024-11-19, names Zetta in an $8 million pre-seed for clinician-led therapy with an AI assistant. It does not establish brain recording or stimulation. Likewise, Nabla Bio and Phylo's broad biology focus does not establish neuroscience-specific investing. No additional verified BCI or neuromodulation investment was found in the sources checked. Searches also surfaced unrelated **Zetta AI** connectomics work; name similarity is insufficient evidence of investment and it was excluded.
## Conflicts, missing information and later Adex review
- Preserve this exact firm ID. Public name, official site and San Francisco address align; do not merge unrelated Zetta AI, Zetta Genomics, Zeta Global or cloud-storage businesses.
- Add fund vintages/status with dated citations if reviewed later: Fund IV's sold-versus-offered distinction is essential. Current final close, current AUM and current firm check range remain unverified.
- Snapshot roles include Ash Fontana, James Alcorn, Léo Jianoti and Cathrin Stickney alongside others. The [current official team page](https://www.zettavp.com/team ), undated, accessed 2026-10-06, lists Mark Gorenberg, Apoorva Pandhi, Dylan Reid, Annelies Gamble and Jocelyn Goldfein. Omission is not proof of a departure date, but snapshot roles require current/historical reconciliation.
- Review EnsoData's snapshot June 2022 “Series A” as an **extension**, and populate its verified 2020 and 2025 dates/lead attribution where appropriate. The June 2025 round was led by Questa, with Zetta participating.
- Snapshot participation `amount` fields often contain the full funding round total while `roundAmount` is null. None of the checked announcements discloses Zetta's individual allocation; do not retain these as confirmed investor checks without review.
- Snapshot duplicates/aliases include Pulse Security dated/year-only entries, Fixie/Fixie.ai, Gable/Gable Ai, Jimini/JIMINI HEALTH, Myia/Myia Health and EnsoData dated/undated rounds. These are reconciliation leads, not proof every pair is identical. Guardrails/Guardrails AI should likewise be checked.
- Add Boltz as a firm-specific primary-source research lead; prioritize computational-biology examples and EnsoData EEG diagnostics for deep-tech/neurotech review. Avoid interpreting all 50 inherited participations as separately verified transactions.
This report is focused verification rather than an exhaustive portfolio audit. All linked sources were accessed 2026-10-06. Publication dates are stated above where available; undated pages carry the access date. Research-only output: no MCP Patch, database modification or commit. SHOW MORE
team@apexlogos.ai · 5 hours ago
Match research 2026-10-06 / GoldiZettaVenturePartners / sha256:e7b8393dfdffc62589289ef68ef84e89b9820f9d7ef916cb98cc9db18bfe95d4 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# Zetta Venture Partners
- Exact Adex ID: `GoldiZettaVenturePartners`
- Canonical Adex URL: https://adex.page/firms/GoldiZettaVenturePartners
- Official website: https://www.zettavp.com/
- Research date and source access date: 2026-10-06
- Status: complete research report; no Adex/database edits performed.
Zetta is a San Francisco-based venture investor focused on AI-native companies, with verified early investments in computational biology and clinical waveform analysis. EnsoData is a specifically verified neurotechnology-related investment through EEG sleep scoring, although it is a software diagnostics company rather than a BCI or neuromodulation device company. The most recent fund vehicle verified here is Fund IV: its May 2025 SEC amendment reported $85.395 million sold against a $150 million offering; a final close was not verified.
## Starting evidence: Adex and NFX Signal
The saved exact-ID snapshot, `data/research/_sources/GoldiZettaVenturePartners.adex.json`, was retrieved 2026-10-06 at 19:29:05 UTC using read-only Adex MCP Search. It identifies the firm as **Zetta Venture Partners**. The `Goldi` prefix belongs to its Adex ID and should not be added to its public name. Its description claims AI-native B2B applications, infrastructure and developer tools, leading pre-seed/seed rounds with $1–5 million checks. Structured check minimum/maximum/sweet spot fields are null. It lists 50 investment participation records, including Phylo, Nabla Bio, EnsoData, Jimini Health, Myia and numerous infrastructure/security businesses. These are inherited claims, not independent proof.
The [NFX Signal firm profile](https://signal.nfx.com/firms/zetta-venture-partners ) was opened directly, but subsequent browser renderings exposed mostly a client-side shell. The search index supplied readable profile text: a historical $60 million first fund, seed/early enterprise analytics investing, anticipated $500,000–$2 million checks, and Ash Fontana's $500,000–$5 million profile range/$1.5 million sweet spot. Signal describes a 2015 launch while its structured founded field says 2014. These are undated, apparently historical claims, accessed 2026-10-06; neither the old fund nor partner profile check range should be presented as current firm terms. The firm's own dated releases say it was founded in 2013, while its playbook describes the first fund launch in 2015: formation and fund launch may account for part, but not all, of the discrepancy. [Official playbook](https://www.zettavp.com/playbook ), undated, accessed 2026-10-06; [2016 firm announcement](https://www.prnewswire.com/news-releases/zetta-closes-100m-expanding-the-first-fund-focused-on-intelligent-enterprise-software-300338889.html ), 2016-10-04.
## Fund size and status
| Vehicle / metric | Amount (USD) | Date and status | Evidence and caveats |
| --- | --- | --- | --- |
| Fund I, historical | $60 million | Historical amount; close date not established here | Signal's first-fund claim is consistent with the 2016 release's $160 million total AUM less its $100 million Fund II. This arithmetic corroborates scale, not a precise Fund I closing date. |
| Fund II | $100 million | Closed, announced 2016-10-04 | [Firm-issued announcement](https://www.prnewswire.com/news-releases/zetta-closes-100m-expanding-the-first-fund-focused-on-intelligent-enterprise-software-300338889.html ) explicitly calls this its second fund and reports $160 million AUM at that time. |
| Fund III | $180 million | Fund announced 2020-04-14 | [Firm-issued announcement](https://www.prnewswire.com/news-releases/zetta-venture-partners-fuels-the-future-of-ai-with-180-million-fund-301040135.html ) identifies its third fund and $365 million total AUM. It describes an announced fund rather than an unraised target; the exact legal final-close date was not established. |
| Fund IV, L.P. | $150 million offering; $85.395 million sold; $64.605 million remaining | SEC Form D/A filed 2025-05-30; first sale 2024-05-31 | [SEC filing](https://www.sec.gov/Archives/edgar/data/2024392/000202439225000001/xslFormDX08/primary_doc.xml ), CIK 2024392. Formed in 2024; 34 investors reported. Amount sold is a fundraising snapshot, not proof of a $150 million final close. |
Fund IV is the latest-known vehicle located in these checks, not a claim that no later fund exists. No newer official close announcement was verified through searches for 2025–2026 fundraising. The $365 million AUM figure is dated 2020 and is not current AUM. The 2016 and 2020 AUM totals should not be mechanically reconciled by summing initial announced fund amounts: later upsizing or other capital may explain the difference, but was not established. Fund size, AUM, portfolio round totals and individual checks remain separate metrics.
## Investment stages and current strategy
The [official homepage](https://www.zettavp.com/ ), undated, accessed 2026-10-06, describes inception-stage support for AI-native applications, infrastructure and developer tools. The [official playbook](https://www.zettavp.com/playbook ), same access date, identifies AI-driven B2B businesses and applications in biotechnology, climate, cloud infrastructure and security. [Zetta's counsel's Guardrails AI deal announcement](https://www.lowenstein.com/news-insights/firm-news/lowenstein-represents-zetta-venture-partners-in-seed-funding-round-in-guardrails-ai ), indexed as March 2024, explicitly describes a pre-seed/seed lead strategy.
The 2020 firm release states a historical initial commitment of $1–3 million and pre-traction B2B AI focus. The snapshot's $1–5 million range was not independently verified as current official policy. Historical Series A/B participation below demonstrates follow-on investing, not an unrestricted late-stage entry mandate.
## Named previous deep-tech investments
Amounts below are entire company rounds, **not Zetta's individual investment amounts**. Firm participation is attributed to Zetta itself, rather than inferred from a partner's earlier employment.
| Company | Technology rationale and classification | Verified firm attribution / transaction | Sources and dates |
| --- | --- | --- | --- |
| **Nabla Bio** | Generative protein models combined with experimental functional screening to design antibodies. Strong computational-biotechnology deep-tech example; no specific neurotechnology product verified. | Zetta and Khosla co-led the $11 million seed in 2021; Zetta participated in the $26 million Series A led by Radical Ventures in May 2024. | [Official Zetta company profile](https://www.zettavp.com/companies/nabla ), undated, accessed 2026-10-06; [Zetta-hosted Endpoints report](https://www.zettavp.com/articles/nabla-endpts-series-a ), May 2024. The latter is reproduced reporting on the investor's site, not an independent second source. |
| **Phylo** | Stanford Biomni spinout developing scientific AI agents for biomedical research, integrating biological tools/data and computational analyses. Research-driven scientific software, not a confirmed neural interface. | Zetta participated in a $13.5 million seed co-led by a16z and Menlo's Anthology Fund with Anthropic, announced 2026-02-03. | [Official company announcement](https://phylo.bio/announcement ), 2026-02-03; [SiliconANGLE reporting](https://siliconangle.com/2026/02/03/ai-startup-phylo-nabs-13-5m-integrated-biology-environment/ ), 2026-02-03. |
| **Boltz** | Open scientific AI models for biomolecular structure, interactions and drug design; computational biology deep tech. | Company reports a $28 million seed led by Amplify, a16z and Zetta. This is a named firm co-lead claim. | [Official manifesto](https://www.boltz.com/manifesto ), indexed January 2026, accessed 2026-10-06; [Endpoints funding report](https://endpoints.news/exclusive-boltz-raises-28m-seed-to-build-open-ai-models-in-biology/ ), 2026-01-08. Exact company announcement day not established from readable official page. Boltz is absent from this snapshot and is a review lead. |
| **EnsoData** | Machine learning for physiological waveform interpretation, including EEG sleep-stage/event analysis; clinically regulated scientific software. | $9 million Series A co-led by Zetta and Venture Investors, announced 2020-05-29; Zetta also named as participating in a closed $20 million Series A extension on 2022-06-03 and $20 million Series B on 2025-06-25. | Official company releases: [2020 Series A](https://www.ensodata.com/press_article/9m-series-a-aims-to-extend-adoption-of-waveform-ai-starting-with-sleep-studies/ ), [2022 extension](https://www.ensodata.com/press_article/the-big-news-trifecta-20m-series-a-extension-new-president-back-to-back-best-workplaces/ ), [2025 Series B](https://www.ensodata.com/press_article/ensodata-raises-20m-series-b-to-expand-commercial-team/ ). | SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
JIMINI HEALTH$8M · 2024-11-19
Faro AI$37M · Unknown date
S32
Telmai$5M · 2023-06-15
Andreessen Horowitz
Tabular$— · 2023
Andy McLoughlin
TEST.AI$11M · 2018-07-31
Anna Patterson
Anthony Goldbloom
Sumble$30M · 2025-10-22
Gable$7M · 2023-09-12
Nebulock$— · 2025-07-29
Basis Set Ventures
Falkonry$5M · 2018-06-19
BoxGroup
Cortical Ventures
Weaviate$50M · 2023-04-21
Crane Venture Partners
Fifty Years
Nabla Bio$11M · 2021-12-07Nebulock$25M · Unknown date
General Catalyst
Naive$28M · 2026
Gradient Ventures
Lilt$25M · 2020-05-12
Khosla Ventures
Lan Xuezhao
Nexus Venture Partners
Pear VC
Guardrails AI$7M · 2024-03-11
Scott Sage
Section 32
Uncork Capital
